Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jennifer Rittenberry

Endocrinology, Diabetes & Metabolism Dublin, OH Medical Doctor

NPI 1699797688 CMS profile 1152071

7281 Sawmill Rd, Suite 100, Dublin, OH 43016

Open in the dashboard

General payments

$141,331

865 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jennifer Rittenberry of Dublin, OH is reported in the CMS Open Payments database as having received $141,331 across 865 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $24 1
2023 General $21 1
2021 General $17,668 77
2020 General $39,646 215
2019 General $83,973 571

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Rittenberry
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Jennifer Rittenberry were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Jennifer Rittenberry Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $83,973 $494 $123–$2,253 $163
2020 $39,646 $335 $85–$1,841 $114
2021 $17,668 $398 $88–$1,981 $132
2022 $0 $364 $88–$1,568 $149
2023 $21 $420 $113–$1,614 $160
2024 $24 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novo Nordisk Inc $58,554 181 payments
  2. Mannkind Corporation $58,170 207 payments
  3. Tandem Diabetes Care, Inc. $14,673 59 payments
  4. Valeritas, Inc. $2,704 20 payments
  5. AbbVie, Inc. $986 41 payments
  6. Dexcom, Inc. $940 27 payments
  7. Zealand Pharma US, Inc. $666 2 payments
  8. Janssen Pharmaceuticals, Inc $452 25 payments
  9. Amgen Inc. $395 23 payments
  10. Abbott Laboratories $349 13 payments
  11. Other $3,441 267 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $111,356 108 payments
  2. Food and Beverage $13,144 719 payments
  3. Consulting Fee $11,943 5 payments
  4. Travel and Lodging $4,636 28 payments
  5. Education $252 5 payments
Products named General payments · program years 2019–2024
  1. AFREZZA Diabetes Medicine $32,869 83 payments
  2. Ozempic $30,241 123 payments
  3. AFREZZA Diabetes Medicine $25,301 124 payments
  4. Tresiba $11,562 38 payments
  5. RYBELSUS $10,350 39 payments
  6. t-slim insulin pump $8,146 37 payments
  7. t:slim X2 insulin pump $6,528 22 payments
  8. Victoza $5,102 5 payments
  9. V-GO $3,370 22 payments
  10. CREON $586 22 payments
  11. Other $7,268 535 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

865 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record